Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 25, 2026, at the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Celldex Therapeutics, Inc. (the "Company"), the Company's stockholders approved an amendment (the "Plan Amendment") to the Company's 2021 Omnibus Equity Incentive Plan (the "2021 Plan") (i) increasing the number of shares available for issuance under the 2021 Plan by 3,400,000 shares and (ii) clarifying the tax withholding provisions applicable to awards under the 2021 Plan. The Plan Amendment became effective following its approval by the Company's stockholders.

The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 25, 2026, at the Annual Meeting, the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.

1. The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2027. The tabulation of votes with respect to the election of such directors was as follows:

2. The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. The tabulation of votes with respect to this proposal was as follows:

3. The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares. The tabulation of votes with respect to this proposal was as follows:

4. The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement. The tabulation of votes with respect to this proposal was as follows: